Cargando…

miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway

BACKGROUND: miR-29c has been associated with the progression of many cancers. However, the function and mechanism of miR-29c have not been well investigated in breast cancers. METHODS: Real-time quantitative PCR was used to assess expression of miR-29c and DNMT3B mRNA. Western blot and immunochemist...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wan, Yi, Jie, Zheng, Xiangjin, Liu, Shiwei, Fu, Weiqi, Ren, Liwen, Li, Li, Hoon, Dave S. B., Wang, Jinhua, Du, Guanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956756/
https://www.ncbi.nlm.nih.gov/pubmed/29796115
http://dx.doi.org/10.1186/s13148-018-0495-y
_version_ 1783323942309593088
author Li, Wan
Yi, Jie
Zheng, Xiangjin
Liu, Shiwei
Fu, Weiqi
Ren, Liwen
Li, Li
Hoon, Dave S. B.
Wang, Jinhua
Du, Guanhua
author_facet Li, Wan
Yi, Jie
Zheng, Xiangjin
Liu, Shiwei
Fu, Weiqi
Ren, Liwen
Li, Li
Hoon, Dave S. B.
Wang, Jinhua
Du, Guanhua
author_sort Li, Wan
collection PubMed
description BACKGROUND: miR-29c has been associated with the progression of many cancers. However, the function and mechanism of miR-29c have not been well investigated in breast cancers. METHODS: Real-time quantitative PCR was used to assess expression of miR-29c and DNMT3B mRNA. Western blot and immunochemistry were used to examine the expression of DNA methyltransferase 3B (DNMT3B) protein in breast cancer cells and tissues. The functional roles of miR-29c in breast cancer cells such as proliferation, migration, invasion, colony formation, and 3D growth were evaluated using MTT, transwell chambers, soft agar, and 3D Matrigel culture, respectively. In addition, the luciferase reporter assay was used to check if miR-29c binds the 3′UTR of DNMT3B. The effects of miR-29c on the DNMT3B/TIMP3/STAT1/FOXO1 pathway were also examined using Western blot and methyl-specific qPCR. The specific inhibitor of STAT1, fludarabine, was used to further check the mechanism of miR-29c function in breast cancer cells. Studies on cell functions were carried out in DNMT3B siRNA cell lines. RESULTS: The expression of miR-29c was decreased with the progression of breast cancers and was closely associated with an overall survival rate of patients. Overexpression of miR-29c inhibited the proliferation, migration, invasion, colony formation, and growth in 3D Matrigel while knockdown of miR-29c promoted these processes in breast cancer cells. In addition, miR-29c was found to bind 3′UTR of DNMT3B and inhibits the expression of DNMT3B, which was elevated in breast cancers. Moreover, the protein level of TIMP3 was reduced whereas methylation of TIMP3 was increased in miR-29c knockdown cells compared to control. On the contrary, the protein level of TIMP3 was increased whereas methylation of TIMP3 was reduced in miR-29c-overexpressing cells compared to control. Knockdown of DNMT3B reduced the proliferation, migration, and invasion of breast cancer cell lines. Finally, our results showed that miR-29c exerted its function in breast cancers by regulating the TIMP3/STAT1/FOXO1 pathway. CONCLUSION: The results suggest that miR-29c plays a significant role in suppressing the progression of breast cancers and that miR-29c may be used as a biomarker of breast cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0495-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5956756
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59567562018-05-24 miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway Li, Wan Yi, Jie Zheng, Xiangjin Liu, Shiwei Fu, Weiqi Ren, Liwen Li, Li Hoon, Dave S. B. Wang, Jinhua Du, Guanhua Clin Epigenetics Research BACKGROUND: miR-29c has been associated with the progression of many cancers. However, the function and mechanism of miR-29c have not been well investigated in breast cancers. METHODS: Real-time quantitative PCR was used to assess expression of miR-29c and DNMT3B mRNA. Western blot and immunochemistry were used to examine the expression of DNA methyltransferase 3B (DNMT3B) protein in breast cancer cells and tissues. The functional roles of miR-29c in breast cancer cells such as proliferation, migration, invasion, colony formation, and 3D growth were evaluated using MTT, transwell chambers, soft agar, and 3D Matrigel culture, respectively. In addition, the luciferase reporter assay was used to check if miR-29c binds the 3′UTR of DNMT3B. The effects of miR-29c on the DNMT3B/TIMP3/STAT1/FOXO1 pathway were also examined using Western blot and methyl-specific qPCR. The specific inhibitor of STAT1, fludarabine, was used to further check the mechanism of miR-29c function in breast cancer cells. Studies on cell functions were carried out in DNMT3B siRNA cell lines. RESULTS: The expression of miR-29c was decreased with the progression of breast cancers and was closely associated with an overall survival rate of patients. Overexpression of miR-29c inhibited the proliferation, migration, invasion, colony formation, and growth in 3D Matrigel while knockdown of miR-29c promoted these processes in breast cancer cells. In addition, miR-29c was found to bind 3′UTR of DNMT3B and inhibits the expression of DNMT3B, which was elevated in breast cancers. Moreover, the protein level of TIMP3 was reduced whereas methylation of TIMP3 was increased in miR-29c knockdown cells compared to control. On the contrary, the protein level of TIMP3 was increased whereas methylation of TIMP3 was reduced in miR-29c-overexpressing cells compared to control. Knockdown of DNMT3B reduced the proliferation, migration, and invasion of breast cancer cell lines. Finally, our results showed that miR-29c exerted its function in breast cancers by regulating the TIMP3/STAT1/FOXO1 pathway. CONCLUSION: The results suggest that miR-29c plays a significant role in suppressing the progression of breast cancers and that miR-29c may be used as a biomarker of breast cancers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0495-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-16 /pmc/articles/PMC5956756/ /pubmed/29796115 http://dx.doi.org/10.1186/s13148-018-0495-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Li, Wan
Yi, Jie
Zheng, Xiangjin
Liu, Shiwei
Fu, Weiqi
Ren, Liwen
Li, Li
Hoon, Dave S. B.
Wang, Jinhua
Du, Guanhua
miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title_full miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title_fullStr miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title_full_unstemmed miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title_short miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway
title_sort mir-29c plays a suppressive role in breast cancer by targeting the timp3/stat1/foxo1 pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956756/
https://www.ncbi.nlm.nih.gov/pubmed/29796115
http://dx.doi.org/10.1186/s13148-018-0495-y
work_keys_str_mv AT liwan mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT yijie mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT zhengxiangjin mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT liushiwei mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT fuweiqi mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT renliwen mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT lili mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT hoondavesb mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT wangjinhua mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway
AT duguanhua mir29cplaysasuppressiveroleinbreastcancerbytargetingthetimp3stat1foxo1pathway